The aim of this study was to evaluate the efficacy and tolerability of valsartan, a new angiotensin II receptor antagonist, versus atenolol in the treatment of severe primary hypertension. A total of 103 adult out-patients were randomised to receive either valsartan 160 mg or atenolol 100 mg once daily for 6 weeks. If necessary, additional blood pressure (BP) control could be provided as add-on therapy. Both valsartan and atenolol decreased mean sitting diastolic BP (DBP) and mean sitting systolic BP (SBP): least squares mean change from baseline in DBP; valsartan, ؊20.0 mm Hg; atenolol, ؊20.4 mm Hg: in SBP; valsartan, ؊30.0 mm Hg; ateno-
Introduction
Primary hypertension can be controlled by modulation of the renin-angiotensin system, which plays a fundamental role in the regulation of the extracellular fluid volume and blood pressure (BP). 1 Pharmacologically, this has been achieved by inhibiting the angiotensin-converting enzyme (ACE), but this treatment produces characteristic side effects related to inhibition of other ACE substrates. [2] [3] [4] [5] More recently, a novel class of anti-hypertensives has been developed, the angiotensin II receptor antagonists, which specifically and competitively block the AT 1 receptor. 6 Valsartan is a new, orally active, potent and highly selective angiotensin II receptor antagonist 7 which at doses of 80 and 160 mg once daily has been shown to be effective in the treatment of mild to moderate hypertension compared with placebo [8] [9] [10] and to be safe and well tolerated, lacking the side effects characteristic of the ACE inhibitors. 11 To date all published studies have evaluated the use of valsartan in patients with mild to moderate Correspondence: Dr Renata Cifkova, Institute for Clinical and Experimental Medicine, Prague, Czech Republic Received 31 December 1997; revised 10 February 1998; accepted 6 March 1998 lol, ؊25.5 mm Hg. There was no statistically significant difference between the treatment groups. Add-on hydrochlorothiazide (HCTZ) 25 mg was required by 97.2% of patients receiving atenolol and 83.6% of patients receiving valsartan; additional verapamil SR 240 mg was also required by 58.3% of patients receiving atenolol and 64.2% receiving valsartan. Valsartan was well tolerated, with a comparable incidence of treatment-related adverse experiences in both groups.
In conclusion valsartan 160 mg is as well tolerated and effective as atenolol 100 mg in lowering BP in severely hypertensive patients.
hypertension (diastolic BP [DBP] р115 mm Hg). [8] [9] [10] [11] The purpose of the current study was to evaluate the efficacy and tolerability of valsartan in the treatment of patients with severe hypertension, and to compare 160 mg valsartan with a reference anti-hypertensive therapy, 100 mg atenolol, both as initial monotherapy and in combination with other antihypertensive agents.
Patients and methods

Patients
Men and women aged 25-68 with uncomplicated severe primary hypertension (defined as a mean sitting DBP у110 and Ͻ120 mm Hg on randomisation day) were eligible for inclusion in the trial. Patients were either newly diagnosed or had their BP inadequately controlled by their previous treatment. The major exclusion criteria were: secondary hypertension, insulin-dependent diabetes mellitus, serious heart, liver or renal disease, history of cerebrovascular accident, intracranial haemorrhage, hypertensive encephalopathy, serum potassium level Ͻ3.5 mmol/L, urinary tract infection, or clinically significant allergies. Fertile women were required to use effective contraception throughout the trial.
All patients gave written consent to participation in the trial, which was approved by a local Insti-tutional Review Board. The study was performed according to the revised Declaration of Helsinki and Good Clinical Practice requirements. Patients could be withdrawn from the trial if they had intolerable adverse experiences or inadequate therapeutic response resulting in intolerable symptoms and/or DBP Ͻ60 mm Hg or у120 mm Hg, for major violations of the protocol, significant non-compliance, hypokalaemia Ͻ3 mmol/L, or if it was felt to be in the patient's best interest.
Study design
This was a multicentre, randomised, double-blind, active controlled, parallel trial performed in the Czech Republic. After an initial washout period of 3 days, patients were given single-blind placebo for 5 days. This relatively short run-in period (8 days in total) was due to the severity of the hypertensive disease in patients participating in the study. Eligible patients were randomised into two groups to give a 2:1 ratio of valsartan to atenolol treatment, in order to maximise the data obtained from the valsartan treatment group. Patients received either valsartan 160 mg (a dose which has been shown to be effective and safe in patients with mild to moderate hypertension) 11 or atenolol 100 mg (a dose considered comparable to valsartan 160 mg), as two capsules (2 × valsartan 80 mg or 2 × atenolol 50 mg) to be taken once daily at 8 am. Study drugs were supplied in identical capsules to maintain blinding.
Patients were assessed twice during the washout and single-blind placebo treatment periods, once at randomisation (baseline measurement), and again after 1, 2, 3, 4, 5 and 6 weeks of active treatment. Scheduled assessment visits were made in the morning before the study medication for that day was taken, to provide trough BP measurements.
The potential risk of leaving severely hypertensive patients without adequate BP control justified the use of add-on therapies. If necessary, hydrochlorothiazide (HCTZ) 25 mg could be started 2 weeks after randomisation. If BP was still not controlled (a patient was considered to be controlled if the DBP was Ͻ95 mm Hg) at 4 weeks, verapamil SR 240 mg could be given in addition to HCTZ. Thus the data compare valsartan vs atenolol, in both cases with the optional addition of HCTZ and verapamil. The use of other medication which could have interfered with the assessment of end-points was prohibited for the duration of the trial.
The main efficacy variables were the change from baseline in trough DBP and mean sitting systolic BP (SBP) after 6 weeks of treatment or at the time of premature discontinuation. Systolic and diastolic BP was measured at each visit by the same clinician in the same arm using the same sphygmomanometer, and all BP measurements were made using WHO criteria 12 to the nearest 2 mm Hg. For diastolic pressure, phase V (disappearance of Korotkoff sounds) was used.
Other efficacy variables included responder rates (ie, the number of patients who normalised their DBP to Ͻ90 mm Hg or achieved a decrease in DBP of у10 mm Hg compared to baseline), the number of patients whose BP was controlled (DBP Ͻ95 mm Hg), and the change from baseline in standing systolic and diastolic BP at end-point.
The primary criterion for safety and tolerability was the reporting of adverse experiences (AEs). At each visit all AEs which had occurred since the previous visit were recorded, with particular attention paid to reports of orthostatic hypotension, as previously defined, 13 or dry cough. 14 The secondary criteria for safety and tolerability were changes in body weight or heart rate, and any clinically relevant changes in routine haematological and biochemical laboratory findings or 12-lead ECG.
Statistical methodology
As the primary aim of the study was to compare the tolerability and safety profiles of valsartan and atenolol, the intended sample size of 102 patients was determined pragmatically to provide 60 patients exposed to valsartan for at least 6 weeks and allowing for a drop-out rate of 10%. It was calculated that if 50% of atenolol-treated patients reported an AE, this sample size could detect an absolute difference of 30% in comparison with valsartan with 80% power at the 5% significance level. The intent-to-treat population, ie, all randomised patients with at least one post-baseline examination, was used for the statistical analysis.
The changes in DBP and SBP, and the change from baseline in sitting heart rate and body weight, were analysed using a two-way covariance model (ANCOVA) 15 fitting baseline centre and treatment. Treatment-by-baseline and centre-by-treatment interactions were tested for statistical significance. Response rates were analysed using a chi-square test. 16 Analyses were performed at the two-sided 5% significance level.
The incidence of adverse experiences in each treatment group was compared using a chi-square test.
Results
Patients
A total of 103 hypertensive patients were randomised into the two treatment groups: valsartan 160 mg (n = 67) and atenolol 100 mg (n = 36). There were no major differences between the treatment groups in demographics or baseline characteristics (Table 1 ). All patients were Caucasian and the majority were male (70.9%), with proportionately slightly more men in the atenolol (77.8%) than in the valsartan group (67.2%). The median duration of exposure to trial medication for both groups was 42 days. Addon HCTZ was required at some point by a higher percentage of patients receiving atenolol (97.2%) than valsartan (83.6%). However, the further addition of verapamil was needed by a higher percentage of the valsartan group (64.2%, or 76.8% of those already on HCTZ) than the atenolol group (58.3%, or 60% of those already on HCTZ). There was a total of seven premature discontinuations during the trial, with 96 (93%) patients completing the full 6 weeks of active double-blind treatment. Four patients (6%) discontinued from the valsartan group, three (8.3%) from the atenolol group. Most discontinuations were due to adverse experiences (two of four in the valsartan group, all three in the atenolol group).
Efficacy
The results shown are for the intent-to-treat dataset. Both valsartan and atenolol markedly reduced mean sitting diastolic and systolic BPs at the 6-week endpoint (least squares mean change from baseline in DBP: valsartan, −20.0 mm Hg; atenolol, −20.4 mm Hg; least squares mean change from baseline in SBP: valsartan, −30.0 mm Hg; atenolol, −25.5 mm Hg) ( Table 2 ). There was no statistically significant difference between the effect of valsartan 160 mg or atenolol 100 mg on either variable. The profiles of action of both drugs in lowering BP were similar ( Figure 1 ) and indicated that DBP and SBP were still declining at the end of the 6-week study period. No significant treatment-by-baseline or treatment-by-centre interactions were seen. The response rate in the valsartan group (85.1%) was comparable (P = 0.887) to that in the atenolol group (86.1%) ( Table 3 ). Both groups were also comparable in the number of controlled patients, defined as having a DBP р95 mm Hg at end-point (valsartan 59.7%, atenolol 66.7%). The number who had mean DBP р90 mm Hg at end-point was 29 (43.3%) in the valsartan group and 20 (55.6%) in the atenolol group. The mean change from baseline at end-point in standing diastolic and systolic BP was comparable in both treatment groups (valsartan −17.4 and −27.2 mm Hg, atenolol −19.0 and −28.2 mm Hg, for diastolic and systolic BP respectively). 
Safety and tolerability
Both study medications were generally well tolerated. A total of 44 patients (42.7%) reported one or more AE, whether or not it was related to trial drug medication. Of these, 26 (38.8%) were in the valsartan group and 18 (50%) in the atenolol group. Most reported AEs were mild to moderate in severity. Seventeen (25.4%) patients in the valsartan group and nine (25.0%) patients in the atenolol group reported AEs that the investigator considered to be at least possibly related to trial medication. The most common drug-related AEs in the valsartan group were fatigue (11.9%), headache (6.0%) and dizziness (6.0%) ( Table 4 ). The commonest drugrelated AE in patients receiving atenolol was headache (11.1%), while fatigue, dyspnea and muscle weakness were each reported by two patients (5.6%) in the atenolol group. Dry cough of mild severity and considered to be treatment-related was reported by one patient (1.5%) in the valsartan group and by none in the atenolol group. No patients reported orthostatic hypotension.
Only two patients had AEs considered to be serious and at least possibly drug-related. Two further patients prematurely discontinued for reasons considered probably related to trial treatment: one in the valsartan group for hypokalaemia after having received HCTZ as add-on therapy for 2 weeks, and one in the atenolol group for mild dyspnea.
The change in sitting heart rate showed a statistically significant difference between the valsartan and atenolol groups (least squares mean change in sitting heart rate from baseline on valsartan was −1.8 beats/min, on atenolol −7.3, P Ͻ 0.001). The results were similar for standing heart rate. There was no evidence of a statistically significant effect on body weight or of any clinically relevant ECG or laboratory finding in either treatment group. Creatinine excretion rates in both groups were comparable (valsartan 160 mg: mean change from baseline 0.042 g/8h; atenolol 100 mg: −0.045 g/8h).
Discussion
This is the first study evaluating the safety and efficacy of valsartan 160 mg in patients with severe primary hypertension. The data suggest that valsartan is as effective as the comparator, atenolol. Both treatments produced a clinically significant decrease from baseline in DBP and SBP, with no significant difference observed between the two groups. The comparability of valsartan and atenolol was corrob- Table 4 Incidence of most frequent (Ͼ3%) adverse experiences (AEs) considered drug related orated by the similar responder and controlled BP rates in both groups. One of the main aims of the study was to acquire more data on the systemic safety and tolerability of valsartan 160 mg. The results show that valsartan and atenolol were both well tolerated. A total of 44 of the 103 randomised patients reported adverse experiences, with more patients in the atenolol treatment group reporting AEs (50% vs 38.8%) although there was no significant difference between the groups in the incidence of AEs regardless of trial drug relationship. The commonest AE in valsartantreated patients was fatigue, and in atenolol-treated patients it was headache. Most AEs were considered to be mild or moderate. No orthostatic hypotension was reported. One patient in each treatment group had a serious AE leading to premature withdrawal from the trial.
Previous data showed that valsartan is effective and safe in the treatment of mild to moderate hypertension, but these studies had not been extended to severely hypertensive patients. The treatment of severe hypertension often requires two or more different drugs, although monotherapy would ideally be preferable in terms of convenience and compliance. As expected, it was found that many patients with severe primary hypertension in this study required anti-hypertensive therapy in addition to valsartan or atenolol. Thus the results compare valsartan and atenolol against a background of HCTZ and verapamil therapy. However, by the end of the trial eight (11.9%) patients were still on valsartan monotherapy, compared to only one (2.8%) patient whose BP could be adequately controlled on atenolol alone, suggesting that valsartan may offer some advantage over atenolol in BP control. This might be expected in severe hypertension, where the renin-angiotensin system could play a major role. Direct comparison of these data with another angiotensin II receptor antagonist, losartan, is difficult because the published treatment regimens differ, but indicates that the proportion of patients whose severe hypertension was adequately controlled by valsartan monotherapy is comparable to that reported for at least one trial using losartan. 17 In summary, this study shows that valsartan, a new angiotensin II antagonist, is as effective and well tolerated as atenolol, a first-line treatment in essential hypertension, in reducing BP in severely hypertensive patients. The study suggests that the angiotensin II receptor antagonist valsartan offers a promising alternative to atenolol in the treatment of uncomplicated severe primary hypertension.
